no key · no human

Fierce Biotech API, RSS and sitemap

Every article Fierce Biotech publishes, as JSON, through an open API with no key and no signup. 317 of their articles are indexed right now, refreshed hourly.

United StatesEnglish#6,531 by volume

Four ways to pull fiercebiotech.com

All four are ours, all four are live, and none of them needs a key.

JSON Search this publisher

Every article we hold from fiercebiotech.com, newest first. Add q= to search inside.

curl -s "https://freenewsapi.ai/v1/search?host=www.fiercebiotech.com&size=20"open it →

RSS Subscribe in any reader

The same articles as an RSS 2.0 feed. Works in Feedly, Inoreader, Thunderbird — anywhere.

curl -s "https://freenewsapi.ai/v1/rss?host=www.fiercebiotech.com&size=50"open it →

JSON Feed For apps

JSON Feed 1.1, the same content in a format apps parse natively.

curl -s "https://freenewsapi.ai/v1/feed.json?host=www.fiercebiotech.com&size=50"open it →

Trimmed For agents

Only the fields an agent needs — title, url, date, language — so the response stays small.

curl -s "https://freenewsapi.ai/v1/search?host=www.fiercebiotech.com&size=20&fields=title,url,published_at,lang"open it →

Call the API

A live request. Paste it into a terminal and Fierce Biotech headlines come back as JSON.

bash
curl "https://freenewsapi.ai/v1/search?host=www.fiercebiotech.com&size=5"
317
articles indexed
0
in the last 30 days
7
median per day
1
languages
516 min
median crawl lag
08.06 → 05.08
archive depth

Publishing volume

Articles per day over the last 46 days. The busiest hour is 12:00 UTC — that is when the newsroom pushes its main batch.

2026-06-08: 22 articles2026-06-09: 10 articles2026-06-10: 8 articles2026-06-11: 11 articles2026-06-12: 5 articles2026-06-13: 1 articles2026-06-15: 10 articles2026-06-16: 9 articles2026-06-17: 5 articles2026-06-18: 7 articles2026-06-19: 1 articles2026-06-22: 16 articles2026-06-23: 9 articles2026-06-24: 11 articles2026-06-25: 6 articles2026-06-26: 7 articles2026-06-29: 10 articles2026-06-30: 8 articles2026-07-01: 6 articles2026-07-02: 3 articles2026-07-03: 2 articles2026-07-06: 5 articles2026-07-07: 11 articles2026-07-08: 6 articles2026-07-09: 5 articles2026-07-10: 4 articles2026-07-12: 2 articles2026-07-13: 5 articles2026-07-14: 11 articles2026-07-15: 8 articles2026-07-16: 6 articles2026-07-17: 8 articles2026-07-19: 2 articles2026-07-20: 10 articles2026-07-21: 8 articles2026-07-22: 7 articles2026-07-23: 7 articles2026-07-24: 6 articles2026-07-27: 10 articles2026-07-28: 10 articles2026-07-29: 8 articles2026-07-30: 10 articles2026-07-31: 4 articles2026-08-03: 5 articles2026-08-04: 10 articles2026-08-05: 4 articles06-0806-1606-2507-0607-1407-2207-3108-05
bash
curl "https://freenewsapi.ai/v1/stats?host=www.fiercebiotech.com&top=10"

Publishing rhythm

When Fierce Biotech actually publishes, by hour of day (UTC) and by day of week — measured from 317 timestamps, not from a schedule they advertise.

00: 10001: 10102: 10203: 00304: 30405: 00506: 30607: 30708: 190809: 150910: 61011: 301112: 831213: 531314: 521415: 131516: 71617: 81718: 181819: 101920: 62021: 12122: 52223: 123
Mon: 93MonTue: 86TueWed: 63WedThu: 55ThuFri: 37FriSat: 1SatSun: 4Sun

Sections

Sections come from the publisher's own markup, present on 100% of their articles.

Languages

The site identifies itself under Fierce Biotech, Fierce Healthcare — separate editions publishing under one domain.

CodeLanguageArticlesShare
enEnglish339106.9%

Latest articles

The 18 most recent Fierce Biotech articles in the index — the same rows the API returns, rendered for humans.

Lilly drops another gene therapy trial from $1B Prevail buyout
2026-08-05 13:10 UTC · Biotech · Nick Paul Taylor
The termination further dents the drugmaker’s chances of delivering a return on its investment in Prevail Therapeutics.
Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey
2026-08-05 12:00 UTC · Biotech · Marissa Russo
Expedition secured an oversubscribed $115 million series B from a line-up of big-name investors to propel its lead DPP1 inhibitor through phase 2.
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
2026-08-05 12:00 UTC · Biotech · James Waldron
Novo Nordisk’s CEO admitted the pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular drug ziltivekimab.
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
2026-08-05 11:00 UTC · Biotech · Darren Incorvaia
Attovia plans to use the IPO haul to kick off two large ph. 2 studies for ATTO-1310, a biologic that blocks the itch-inducing interleukin-31.
Icon inks Anthropic partnership to deploy Claude into clinical trials
2026-08-04 20:20 UTC · CRO · Will Maddox
CRO Icon announced a multi-year collaboration with Anthropic this week to bring Claude’s AI capabilities to clinical trials.
Amgen drops early-stage obesity drug, upping pressure on MariTide
2026-08-04 20:01 UTC · Biotech · Darren Incorvaia
The now-canned AMG 513 was previously hit with a clinical hold by the FDA in February 2025, which was lifted a few months later.
Smith & Nephew cuts 2026 outlook as US knee implant sales slide
2026-08-04 19:00 UTC · MedTech · Ayla Ellison
Smith & Nephew has lowered its 2026 sales outlook after weakness in U.S. orthopedics and wound care outweighed stronger growth in sports medicine.
Fiercest Women in Life Sciences 2026: Nominations open now
2026-08-04 14:00 UTC · Pharma · Ayla Ellison
Who should be a 2026 Fiercest Woman in Life Sciences? Nominations are open for women making an impact across pharma, biotech, medtech and beyond.
Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart
2026-08-04 13:37 UTC · Biotech · Marissa Russo
Lisata is laying off 72% of its workforce, including its chief medical officer, after a merger with cancer imaging company Kuva Labs fell apart.
KKR inks $5.7B deal to take medtech manufacturing giant Integer private
2026-08-04 13:09 UTC · MedTech · Joseph Keenan
Private equity giant KKR inked a deal to take medtech manufacturing giant Integer private for approximately $5.7 billion.
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
2026-08-04 12:47 UTC · Biotech · Nick Paul Taylor
Pfizer dropped a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
2026-08-04 11:55 UTC · Biotech · James Waldron
Latigo has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
2026-08-04 11:36 UTC · Biotech · James Waldron
Pathos AI has agreed to pay $125 million for an ADC from China’s Alphamab, while adding a Big Pharma partner in the form of AstraZeneca.
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
2026-08-04 10:30 UTC · Biotech · Nick Paul Taylor
A phase 2 trial of the anti-TL1A antibody missed its primary endpoint, closing off one avenue for expansion of an asset bought in an $11 billion deal.
Curium strikes up to $8B deal for radiopharma rival Lantheus
2026-08-03 18:20 UTC · MedTech · Ayla Ellison
Months after reports first linked Curium to a potential Lantheus takeover, the companies have made it official with a deal worth up to $8 billion.
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
2026-08-03 13:18 UTC · Biotech · James Waldron
BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso.
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
2026-08-03 12:00 UTC · Biotech · Will Maddox
“We want anything that makes sense mechanistically or has proven already to have an effect on MASH,” CEO Bill Sibold told Fierce in an interview.
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
2026-08-03 11:35 UTC · Biotech · James Waldron
One of the most closely watched vacancies in biopharma has been filled, with Sobi CEO Guido Oelkers, Ph.D., taking the top job at mRNA firm BioNTech.

Harvest it all

Page through the archive by date. from and to accept YYYY-MM-DD or relative values such as now-7d.

bash
curl "https://freenewsapi.ai/v1/search?host=www.fiercebiotech.com&from=now-7d&size=100"

To poll for new material, keep the timestamp of the newest article you saw and ask only for what came after it:

bash
curl "https://freenewsapi.ai/v1/search?host=www.fiercebiotech.com&from=now-1h&sort=date_asc"

Article bodies come with full_text=true. No key, no quota tier, no header — see the search endpoint for every parameter.

Metadata quality

How well Fierce Biotech marks up its own pages — useful if you are deciding whether to parse them yourself.

99%
dates from JSON-LD
100%
articles with a byline
100%
articles with sections
826 KB
average page weight

Crawl lag — the delay between publication and the article reaching this index — is 516 min at the median, 1184 minutes at the 90th percentile.

Similar publishers

Comparable outlets in the same language. Those without a page here yet link straight to their slice of the API.

FAQ

Does Fierce Biotech have an official API?

Not a public one. This endpoint is the practical alternative: their articles as structured JSON, with title, lead, publication time, section, byline and a link back to the original.

How do I get their RSS feed?

Most publishers expose one at /rss or /feed, but feeds carry only the last few dozen items and drop them within hours. This index keeps 317 of their articles and lets you filter by date, language and section.

How many articles does Fierce Biotech publish per day?

7 on a median day, measured across 46 days.

Can I use this commercially?

The API is free and unauthenticated. What you may do with the content is between you and the publisher: we return metadata, a lead paragraph and a link, not a licence.